James Engelhart

James Engelhart, listed as finance chief, appears in our data through filings on Biohaven Pharmaceutical Holding Co Ltd. shares, published by SEC (Form 4). Over a trading history stretching from 9 May 2017 to 3 October 2022, the count stands at 42 filings.

Both buying and selling appear: 2 purchases worth €134k, against 17 sales worth €8.7M. Taken together, the sales exceed the purchases by €8.5M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 6 share grants and 15 option exercises.

The latest filing, published on 3 October 2022, reports a transaction of €2.4M in Biohaven Pharmaceutical Holding Co Ltd. The clock since the last published purchase (28 June 2019) now reads 2,675 days. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.